← All Spyre Therapeutics, INC filings

Spyre Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SYRE
Spyre Therapeutics, INC
10-K: Spyre Therapeutics Advances IBD & Rheumatic Disease Pipeline
Spyre Therapeutics, a clinical-stage biotech, reports significant pipeline advancement in IBD and rheumatic diseases, backed by substantial capital raises and positive early clinical data.
NASDAQ
SYRE
Spyre Therapeutics, INC
10-K: Spyre Therapeutics Reports 2024 Financial Results and Provides Business Update
Spyre Therapeutics details its financial performance for 2024 and outlines strategic advancements in its IBD and immune-mediated disease programs.
NASDAQ
SYRE
Spyre Therapeutics, INC
10-K/A: Spyre Therapeutics Files Amended 10-K After Identifying Accounting Error
Spyre Therapeutics has filed an amended 10-K report to correct a misapplication of accounting principles related to the calculation of net loss per share and a material weakness in internal control over financial reporting.
NASDAQ
SYRE
Spyre Therapeutics, INC
10-K/A: Spyre Therapeutics Files Amended 10-K to Include Hyperlinks to Exhibits
Spyre Therapeutics has filed an amendment to its annual report on Form 10-K to include hyperlinks to exhibits that were previously incorporated by reference.
NASDAQ
SYRE
Spyre Therapeutics, INC
10-K: Spyre Therapeutics Reshapes Business, Focuses on IBD Therapies After Asset Acquisition
Spyre Therapeutics has transitioned into a preclinical-stage biotech company focused on developing next-generation treatments for inflammatory bowel disease (IBD) following a strategic asset acquisition and the sale of its legacy assets.